Nanexa shares soar on Novo Nordisk deal worth up to €1.17bn

Nanexa shares rose 114% on Sept 25, 2026, on reports Novo Nordisk will pay up to €1.17bn ($1.33bn) to use its injection technology. For savers, think of it as a promised bonus, not money in the bank: Nanexa only gets it in full if tests and goals are met.